Methods utilizing single cell genetic data for cell population analysis and applications thereof

Patent metadata

Field	Value
Publication number	US-12460260-B2
Application number	US-202016883915-A
Country	US
Kind code	B2
Filing date	May 26, 2020
Priority date	May 23, 2019
Publication date	Nov 4, 2025
Grant date	Nov 4, 2025

Abstract

Processes to infer stemness, cell lineage, and/or differentiation status are provided. In some instances, single cell RNA sequencing is used to infer a cell's stemness, cell lineage, and/or differentiation status. In some instances, a collection of cells is ordered based on each cell's differentiation status.

First claim

What is claimed is:

1 . A method to infer a differentiation status and identify a differentiation-status biomarker from single-cell RNA sequencing of a tissue comprising a mixed population of cells in which the biomarker is prognostic of disease outcome, comprising:
obtaining single cell RNA transcriptome sequencing results of tissues comprising a mixed population of cells, wherein the sequencing was performed on each single cell individually and each cell's sequencing result includes the cell's gene expression; generating a matrix of cell×cell's gene expression for the population of cells from the sequencing results; determining a gene count signature for the population of cells, wherein the gene count signature is a surrogate for whole transcriptome gene counts and defined as a geometric mean of the expression level of each gene of a set of five or more genes that are most correlated with gene counts within the population of cells; computing a gene count signature metric for each cell; determining the differentiation status of each cell of the population of cells relative to each other based on ranking each cell's smoothed gene count signature metric, wherein cells having a smoothed gene count signature metric indicative of lower gene counts are more differentiated than cells having a smoothed gene count signature metric indicative of higher gene counts; wherein each cell's smoothed gene count signature metric comprises denoising the gene count signature metric by:
identifying transcriptionally similar cells within the population of cells utilizing a neighboring technique and the matrix of cell×cell's gene expression; and
smoothing the gene count signature metric by:
applying a regression technique to determine coefficients that best fit the gene count signature to the neighboring technique; and
simulating a diffusion process to iteratively adjust the gene count signature for a number of iterations or until convergence;

identifying a differentiation-status biomarker that is expressed in a subset of cells of the population of cells, wherein each cell of the subset of cells is determined to have the same differentiation status by their smoothed gene count signature metric rank, wherein the differentiation-status biomarker is uniquely expressed within the subset of cells as compared to the whole population of cells establishing that the differentiation-status biomarker is a gene product indicative of the differentiation status of the subset of cells, wherein the subset of cells has a putative effect on disease prognosis based on its differentiation status; determining the biomarker is prognostic of disease by modulating gene expression of the biomarker in an experimental model that is representative of the disease; performing a prognostic assay on a patient tissue sample comprising a mixture of cells having varying degrees of differentiation, wherein the prognostic assay comprises one of the following:
detecting RNA expression of the biomarker within the patient tissue sample by nucleic acid hybridization; or
detecting protein expression of the biomarker within the patient tissue sample by immunodetection.

2 . The method of claim 1 further comprising:
obtaining the tissues comprising a mixed population of cells;
separating the tissues into individual cells;
extracting RNA from each individual cell; and
sequencing each individual cell's RNA to yield a single cell sequencing result for each individual cell, wherein each single cell sequencing result includes each cell's gene expression profile.

3 . The method of claim 1 , wherein the tissues are derived from one or more tissue biopsies, wherein the tissue is selected from: blood, brain, lymph node, thymus, bone marrow, spleen, skeletal muscle, heart, colon, stomach, small intestine, kidney, liver, skin, and lung.

4 . The method of claim 1 , wherein the tissues comprise a neoplasm.

5 . The method of claim 1 , wherein each cell's gene expression is normalized for sequencing depth by rescaling a total number of reads per single cell.

6 . The method of claim 1 , wherein cells having a total number of detectable genes below a certain threshold are removed from further analysis.

7 . The method of claim 1 , wherein the number of genes in the set of genes is between 5 and 1000.

8 . The method of claim 1 , wherein the genes in the set of genes consist of between 5 and 200 genes, wherein the set of genes are the top genes that are most correlated with gene counts, as determined using the obtained single cell sequencing results.

9 . The method of claim 8 , wherein expression of each gene of the set of genes is positively correlated with total gene count.

10 . The method of claim 1 , wherein the neighboring technique is one of: an adjacency matrix, similarity matrix, or a Markov process.

11 . The method of claim 1 further comprising:
ordering the cells based on their differentiation status.

12 . The method of claim 1 further comprising:
identifying at least one cell of the population of cells to be one of: a tumor initiating cell, a stem cell, a progenitor cell, or a differentiated cell based on the differentiation status.

13 . The method of claim 1 further comprising:
performing an immunodetection technique on a second mixed population of cells to label a subset of cells that expresses the differentiation-status biomarker; and
performing flow cytometry to isolate the labeled subset of cells from the second mixed population.

14 . The method of claim 1 ,
wherein modulating gene expression of the biomarker in an experimental model comprises the use of one of: a short-hairpin RNA, CRISPR, antigen binding protein, a small molecule antagonist, and a small molecule agonist.

15 . The method of claim 1 , wherein the disease is cancer, the subset of cells determined to have the same differentiation status is one or more of: progenitor cells, tumor initiating cells, cancer stem cells, or quiescent cells.

16 . The method of claim 15 further comprising:
treating the patient with a therapy based on the prognostic indication of the disease provided by detection of RNA expression of the biomarker or protein expression of the biomarker.

17 . The method of claim 16 , wherein the subset of cells determined to have the same differentiation status comprises a quiescent cancer stem cell; wherein the method further comprises:
administering a chemoquiescence agent and a chemotherapeutic agent to the patient.

18 . A method to identify quiescent stem cells within a plurality of cells and identify biomarkers of the quiescent stem cells within a cancer, comprising:
obtaining single cell RNA transcriptome sequencing results of tissues comprising a mixed population of cells, wherein the sequencing was performed on each single cell individually and each cell's sequencing result includes the cell's gene expression, wherein the tissues comprise a cancer tissue; generating a matrix of cell×cell's gene expression for the population of cells from the sequencing results; determining a gene count signature for the population of cells, wherein the gene count signature is a surrogate for whole transcriptome gene counts and defined as a geometric mean of the expression level of each gene of a set of five or more genes that are most correlated with gene counts within the population of cells; computing a gene count signature metric for each cell; identifying stem cells by determining a differentiation status of each cell of the population of cells relative to each other by;
det

Assignees

• Univ Leland Stanford Junior
• The Board Of Trustees Of Leland Stanford Junior Univ

Inventors

• Newman Aaron M
• Gulati Gunsagar S
• Clarke Michael F
• Sikandar Shaheen Shabbir

Classifications

• C12Q1/6883

  for diseases caused by alterations of genetic material · CPC title

• C12N15/113

  Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} · CPC title

• C12N5/0068

  General culture methods using substrates (for specific animal cell type C12N5/06) · CPC title

• C12N2506/30

  from cancer cells, e.g. reversion of tumour cells · CPC title

• G16B20/00

  ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations · CPC title